Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
15-deoxy-Δ12,14-prostamide j2
- Development stage
- Preclinical
- Lead developer
- East Carolina University
- Modality
- Small Molecules
- Administration
- Intratumoral
01
Overview
15-deoxy-Δ12,14-prostamide J2 (15d-PMJ2) is an investigational small-molecule research compound and an endocannabinoid metabolite. It is produced through the metabolism of arachidonoyl ethanolamide (AEA) by cyclooxygenase-2 (COX-2). 15d-PMJ2 selectively induces apoptosis in various cancer cells, including melanoma, non-melanoma skin cancer (NMSC), and colon cancer, while sparing non-tumorigenic cells. Its mechanism of action involves the induction of endoplasmic reticulum (ER) stress, specifically activating the PERK and CHOP10 pathways, and triggering calcium mobilization from the ER to the mitochondria via the inositol 1,4,5-trisphosphate receptor (IP3R). This calcium flux leads to the opening of the mitochondrial permeability transition pore and subsequent cell death. The compound's cytotoxic activity is dependent on an electrophilic double bond within its cyclopentenone ring. 15d-PMJ2 has demonstrated efficacy in reducing tumor growth in murine melanoma models and is primarily being investigated by academic researchers at East Carolina University.
- Other names
- 15-deoxy-Δ12,14-prostaglandin J2-ethanolamide15-deoxy-Δ12,14 prostamide J2
02
Targets
ChoP (Phosphorylcholine)EIF2AK3 (Pkr-like endoplasmic reticulum kinase)IP3R (Inositol Trisphosphate Receptor)MPTP (Mitochondrial permeability transition pore)
Beyond the preview
Go deeper on 15-deoxy-Δ12,14-prostamide j2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 15-deoxy-Δ12,14-prostamide j2.